Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Nervous Tissue: Myelin01:25

Nervous Tissue: Myelin

The myelin sheath is a multilayered lipid and protein covering that insulates the axon of a neuron, enhancing the speed of nerve impulse conduction. Axons without this sheath are referred to as unmyelinated. Two types of neuroglia, Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS) are responsible for producing myelin sheaths.
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Glial Cells01:04

Glial Cells

Overview
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional exploration of metabotropic glycine receptors in cultured rat hippocampal slices.

Neuroreport·2026
Same author

Cerebello-Brainstem Dominant Form of X-linked Adrenoleukodystrophy Without Apparent Brain MRI Abnormalities at Disease Onset.

Cerebellum (London, England)·2026
Same author

Biologic therapy and brain atrophy in neuromyelitis optica: a Japanese-German longitudinal MRI study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Headache prevalence and types in multiple sclerosis and related neuroimmunological diseases: A multicenter study.

Cephalalgia : an international journal of headache·2026
Same author

Spinocerebellar Ataxia Type 6 Initially Diagnosed as Alcoholic Cerebellar Degeneration: A Case Report.

Internal medicine (Tokyo, Japan)·2026

Related Experiment Video

Updated: Jul 5, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Peripheral nerve demyelination in multiple sclerosis.

Sonoko Misawa1, Satoshi Kuwabara1, Masahiro Mori1

  • 1Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan.

Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology
|May 23, 2008
PubMed
Summary

Peripheral nerve demyelination is uncommon in multiple sclerosis (MS), affecting approximately 5% of patients. This demyelinating neuropathy often occurs years after MS onset and may share a common pathogenesis.

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Related Experiment Videos

Last Updated: Jul 5, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Area of Science:

  • Neuroscience
  • Neurology
  • Immunology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Peripheral neuropathy, particularly demyelinating forms, has been anecdotally reported in MS patients.
  • The precise frequency of peripheral nerve demyelination in the general MS population remains unclear.

Purpose of the Study:

  • To determine the prevalence of peripheral nerve demyelination in patients with relapsing-remitting multiple sclerosis.
  • To investigate the clinical and electrophysiological characteristics of demyelinating neuropathy in MS.

Main Methods:

  • Prospective study involving 60 consecutive relapsing-remitting MS patients.
  • Comprehensive nerve conduction studies were performed on all participants.
  • Threshold tracking excitability measurements were utilized on median motor and superficial radial sensory axons.

Main Results:

  • Nerve conduction abnormalities indicative of demyelination were identified in 3 patients (5%).
  • Two patients presented with clinically apparent neuropathy; one had generalized areflexia.
  • In all affected individuals, MS diagnosis preceded the onset of demyelinating neuropathy by several years.

Conclusions:

  • Peripheral nerve demyelination is not a general feature of MS but occurs in approximately 5% of cases.
  • The co-occurrence of MS and demyelinating neuropathy may stem from shared pathogenic mechanisms, potentially involving epitope spreading.
  • Chronic inflammatory demyelinating polyneuropathy associated with MS, though infrequent, is a recognizable and treatable condition.